The European Commission has granted approval to Novartis for the use of Cosentyx (secukinumab) in treating adults with moderate to severe hidradenitis suppurativa (HS). This decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) and is based on results from the SUNSHINE and SUNRISE Phase III clinical trials.

Cosentyx is now authorized as a treatment option for HS, a chronic inflammatory skin condition that significantly impacts patients' quality of life. The approval marks an expansion of Cosentyx's indications in Europe, where it is already used for conditions such as psoriasis and psoriatic arthritis.

Healthcare professionals across Europe can now consider Cosentyx as part of their therapeutic arsenal for managing HS, offering new hope for patients with limited treatment options. For more information, visit the official Novartis website or the European Medicines Agency's announcement.